VANDA PHARMACEUTICALS INC. (NASDAQ:VNDA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02.
(b) Resignation of Named Executive Officer
On March 8, 2017, Paolo Baroldi, M.D. notified Vanda Pharmaceuticals Inc. (the “Company”) of his resignation as the Company’s Chief Medical Officer effective as of March 22, 2017.
1
About VANDA PHARMACEUTICALS INC. (NASDAQ:VNDA)
Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. The Company offers HETLIOZ (tasimelteon) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). The Company offers Fanapt (iloperidone) for the treatment of schizophrenia. Additionally, its distribution partners launched Fanapt in Israel and Mexico. Tradipitant (VLY-686) is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. It is indicated for the treatment of CNS Disorders. VANDA PHARMACEUTICALS INC. (NASDAQ:VNDA) Recent Trading Information
VANDA PHARMACEUTICALS INC. (NASDAQ:VNDA) closed its last trading session down -0.05 at 14.90 with 400,391 shares trading hands.